Hanxiao Chen

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Treatment patterns and outcomes of second/third-line therapy in advanced non-small cell lung cancer with actionable genomic alterations (RECAP).

Treatment patterns and outcomes of second/third-line therapy in advanced non-small cell lung cancer with actionable genomic alterations (RECAP).

Journal: Clinical & experimental metastasis

Published: May 29, 2026

Treatment patterns and outcomes of later-line therapy in advanced non-small cell lung cancer with unknown or no actionable genomic alterations: a multicenter real-world study in China (RECAP study).

Treatment patterns and outcomes of later-line therapy in advanced non-small cell lung cancer with unknown or no actionable genomic alterations: a multicenter real-world study in China (RECAP study).

Journal: Translational lung cancer research

Published: March 30, 2026

Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression.

Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression.

Journal: Current oncology (Toronto, Ont.)

Published: March 17, 2026

Surgical management of the primary tumor in stage M1a-IVA non-small cell lung cancer.

Surgical management of the primary tumor in stage M1a-IVA non-small cell lung cancer.

Journal: The Journal of thoracic and cardiovascular surgery

Published: February 12, 2026

Prognostic significance of micropapillary pattern and risk factors in patients with resected stage I lung adenocarcinoma and possible benefit of adjuvant therapy: a real-world multicenter study.

Prognostic significance of micropapillary pattern and risk factors in patients with resected stage I lung adenocarcinoma and possible benefit of adjuvant therapy: a real-world multicenter study.

Journal: Translational lung cancer research

Published: June 17, 2025

Prognostic utility of baseline ASCL1/INSM1 expression and neutrophil-lymphocyte ratio in unresectable SCLC treated with first-line chemoimmunotherapy with or without radiotherapy.

Prognostic utility of baseline ASCL1/INSM1 expression and neutrophil-lymphocyte ratio in unresectable SCLC treated with first-line chemoimmunotherapy with or without radiotherapy.

Journal: Frontiers of medicine

Published: June 11, 2025

Treatment Efficacy, Chemoradiotherapy Benefits, and Survival Disparities by Histology in Primary Mediastinal Germ Cell Tumors: 15-Year Results of a Single-Center Cohort Study.

Treatment Efficacy, Chemoradiotherapy Benefits, and Survival Disparities by Histology in Primary Mediastinal Germ Cell Tumors: 15-Year Results of a Single-Center Cohort Study.

Journal: Asia-Pacific journal of clinical oncology

Published: April 01, 2025

Prevalence, genetic variations and clinical outcomes of BRAF-V600 mutated advanced NSCLC in China: a retrospective real-world multi-centre study.

Prevalence, genetic variations and clinical outcomes of BRAF-V600 mutated advanced NSCLC in China: a retrospective real-world multi-centre study.

Journal: EBioMedicine

Published: June 26, 2024

Women patients with small-cell lung cancer using immunotherapy in a real-world cohort achieved long-term survival.

Women patients with small-cell lung cancer using immunotherapy in a real-world cohort achieved long-term survival.

Journal: Thoracic cancer

Published: April 12, 2024

Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas.

Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: November 14, 2023

Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis.

Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 07, 2023

High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial.

High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial.

Journal: The Lancet. Respiratory medicine

Published: November 05, 2023

Showing 1-12 of 47

Last Updated: 09/26/2026